ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...

Subgroup analysis revealed a pronounced effect among patients receiving MAC. In this cohort, 6-month grade 2-4 GFS was 35.7% with placebo vs 60.7% with ustekinumab (OR 2.78 for failure; 80% CI, 1.19-6 ...

Claims of differential treatment effects were largely rated as “low credibility” or “very low credibility.” Subgroup analyses in cancer trials may not be credible, and their results should be ...

QUEENSBURY, N.Y., December 31, 2025--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and ...

Myosteatosis on computed tomography as a predictor of therapeutic response to CDK4/6 inhibitors plus aromatase inhibitors in patients with advanced breast cancer. Subgroup OS HR (95% CI) OS p-value ...

A meta-analysis of more than 20 phase 3 trials found no clear survival differences by sex or age in metastatic NSCLC but ...

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma A total of 221 publications reporting data on ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...

This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” Clinical trials of newly developed drugs often don’t ...